洛卡格拉米德通过调节IL-4受体信号传递来抑制过敏反应
Hyein Jo1, Misun Kim1, Jaewhoon Jeoung1
1Department of Biochemistry, Kangwon National University, Chuncheon 24341, Republic of Korea.
Molecules (Basel, Switzerland)
|February 26, 2025
概括
洛卡格拉米德 (Roc-A) 通过抑制介素-4受体 (IL-4R) 信号传递来抑制过敏性炎症,这为新的抗过敏疗法提供了潜力. 这种天然化合物影响关键的过敏路径和巨细胞两极分化.
科学领域:
- 免疫学 免疫学 免疫学
- 药理学 药理学是指药理学的学科.
- 自然产品 化学 化学
背景情况:
- 过敏性炎症会加剧癌症的进展.
- 洛卡格拉米德 (Roc-A) 是一种来自Aglaia物种的植物化学物质,具有抗癌性质.
- 洛克-A在调节过敏炎症方面的潜力尚未被探索.
研究的目的:
- 为了研究Roc-A对过敏炎症的影响.
- 为了阐明Roc-A抗过敏作用背后的分子机制.
- 探索白蛋白-4受体 (IL-4R) 在Roc-A治疗潜力的作用.
主要方法:
- 在体外检测过敏反应的标志.
- 被动皮肤过敏反应 (PCA) 和被动系统性过敏反应 (PSA) 的模型.
- RNA测序,分子对接和染色体免疫沉 (ChIP) 试验.
- 对巨细胞极化标记物的分析 (M1/M2).
主要成果:
- 在体外和体内 (PCA/PSA) 抑制Roc-A抗原诱导的过敏反应.
- 洛克-A抑制了IL-4和IL-4R的表达,并阻止IL-4R与JAK1.1结合.
- Roc-A调节了巨细胞极化,并影响了miR-34a的表达,这是IL-4R的负调节者.
- 分子对接确定了潜在的IL-4R结合化学物质,包括1536801,具有抗过敏作用.
结论:
- 通过准IL-4R通路,Roc-A显示出显著的抗过敏特性.
- 洛克-A的抗过敏作用与miR-34a调节和巨细胞极化调节有关.
- 准IL-4R为开发新型抗过敏疗法提供了一个有前途的战略.
相关概念视频
Antiasthma Drugs: Mast Cell Stabilizers and Anti-IgE Drugs
226
Asthma is a chronic respiratory condition for which new therapeutic avenues, including anti-inflammatory drugs like mast cell stabilizers and anti-IgE treatments, continue to be developed.
Mast cell stabilizers, such as cromolyn (also known as sodium cromoglycate) and nedocromil (Tilade), are effective drugs in asthma management. These stabilizers hinder histamine release by skillfully obstructing the activation of mast cells and other cellular entities. Notably, they navigate this task without...
Mast cell stabilizers, such as cromolyn (also known as sodium cromoglycate) and nedocromil (Tilade), are effective drugs in asthma management. These stabilizers hinder histamine release by skillfully obstructing the activation of mast cells and other cellular entities. Notably, they navigate this task without...
226
GPCRs Regulate Adenylyl Cylase Activity
5.1K
Some GPCRs transmit signals through adenylyl cyclase (AC), a transmembrane enzyme. AC helps synthesize second messenger cyclic adenosine monophosphate (cAMP). AC catalyzes cyclization reaction and converts ATP to cAMP by releasing a pyrophosphate. The pyrophosphate is further hydrolyzed to phosphate by the enzyme pyrophosphatase, which drives cAMP synthesis to completion. However, cAMP is rapidly degraded to 5′ AMP by the enzymes phosphodiesterase (PDE), preventing overstimulation of...
5.1K
Glucagon-like Receptor Agonists
291
Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
291
Allergic Drug Reactions
804
Allergic reactions related to drugs are hypersensitivity responses driven by the immune system and bear no connection to the drug's therapeutic action. While drugs in isolation do not trigger an immune response, they can interact with endogenous proteins to form antigens. These antigens stimulate lymphocytes to produce antibodies. IgE-type antibodies attach themselves to mast cells. Upon subsequent exposure to the same stimulus, the antigen-antibody interaction is initiated, unleashing...
804
Allergic Reactions
27.2K
Overview
27.2K
GPCR Desensitization
5.7K
G protein-coupled receptor (GPCR) signaling plays a crucial role in cell functioning. GPCR desensitization is an equally essential process. It allows cells to respond to changing environments and regain sensitivity to new stimuli while preventing unnecessary stimulation when no longer needed. Prolonged exposure to stimuli leads to GPCR desensitization. It involves blocking the receptors from binding and activating additional G proteins. This inhibits activation of downstream effectors, thereby...
5.7K


